565 related articles for article (PubMed ID: 17878176)
1. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
Duffy A; Kortmansky J; Schwartz GK; Capanu M; Puleio S; Minsky B; Saltz L; Kelsen DP; O'Reilly EM
Ann Oncol; 2008 Jan; 19(1):86-91. PubMed ID: 17878176
[TBL] [Abstract][Full Text] [Related]
2. Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study.
Iannitti D; Dipetrillo T; Akerman P; Barnett JM; Maia-Acuna C; Cruff D; Miner T; Martel D; Cioffi W; Remis M; Kennedy T; Safran H
Am J Clin Oncol; 2005 Dec; 28(6):570-5. PubMed ID: 16317266
[TBL] [Abstract][Full Text] [Related]
3. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.
Dragovich T; Huberman M; Von Hoff DD; Rowinsky EK; Nadler P; Wood D; Hamilton M; Hage G; Wolf J; Patnaik A
Cancer Chemother Pharmacol; 2007 Jul; 60(2):295-303. PubMed ID: 17149608
[TBL] [Abstract][Full Text] [Related]
4. Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer.
Konski A; Meyer JE; Joiner M; Hall MJ; Philip P; Shields A; McSpadden E; Choi M; Adaire B; Duncan G; Meropol NJ; Cescon TP; Cohen SJ
Radiother Oncol; 2014 Oct; 113(1):35-40. PubMed ID: 25441058
[TBL] [Abstract][Full Text] [Related]
5. Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer.
Yavuz AA; Aydin F; Yavuz MN; Ilis E; Ozdemir F
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):974-81. PubMed ID: 11704320
[TBL] [Abstract][Full Text] [Related]
6. A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma.
Raftery L; Tepper JE; Goldberg RM; Blackstock AW; Aklilu M; Bernard SA; Ivanova A; Davies JM; O'Neil BH
Am J Clin Oncol; 2013 Jun; 36(3):250-3. PubMed ID: 22547007
[TBL] [Abstract][Full Text] [Related]
7. Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer.
Jiang Y; Mackley HB; Kimchi ET; Zhu J; Gusani N; Kaifi J; Staveley-O'Carroll KF; Belani CP
Cancer Chemother Pharmacol; 2014 Jul; 74(1):205-10. PubMed ID: 24908435
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer.
Martenson JA; Vigliotti AP; Pitot HC; Geeraerts LH; Sargent DJ; Haddock MG; Ghosh C; Keppen MD; Fitch TR; Goldberg RM
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1305-10. PubMed ID: 12654442
[TBL] [Abstract][Full Text] [Related]
9. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
[TBL] [Abstract][Full Text] [Related]
10. Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine.
Kornek GV; Pötter R; Selzer E; Schratter A; Ulrich-Pur H; Rogy M; Kraus G; Scheithauer W
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):665-71. PubMed ID: 11172947
[TBL] [Abstract][Full Text] [Related]
11. Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial.
Girard N; Mornex F; Bossard N; Ychou M; Chauffert B; Wautot V
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1426-32. PubMed ID: 20056351
[TBL] [Abstract][Full Text] [Related]
12. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas.
Blackstock AW; Tepper JE; Niedwiecki D; Hollis DR; Mayer RJ; Tempero MA
Int J Gastrointest Cancer; 2003; 34(2-3):107-16. PubMed ID: 15361643
[TBL] [Abstract][Full Text] [Related]
13. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
Watkins DJ; Starling N; Cunningham D; Thomas J; Webb J; Brown G; Barbachano Y; Oates J; Chau I
Eur J Cancer; 2014 May; 50(8):1422-9. PubMed ID: 24613126
[TBL] [Abstract][Full Text] [Related]
14. A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma.
Budiharto T; Haustermans K; Van Cutsem E; Van Steenbergen W; Topal B; Aerts R; Ectors N; Bielen D; Vanbeckevoort D; Goethals L; Verslype C
Radiat Oncol; 2008 Sep; 3():30. PubMed ID: 18808686
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas.
Pipas JM; Mitchell SE; Barth RJ; Vera-Gimon R; Rathmann J; Meyer LP; Wagman RS; Lewis LD; McDonnell C; Colacchio TA; Perez RP
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1317-22. PubMed ID: 11483344
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study.
Francois E; Bennouna J; Chamorey E; Etienne-Grimaldi MC; Renée N; Senellart H; Michel C; Follana P; Mari V; Douillard JY; Milano G
Chemotherapy; 2012; 58(5):371-80. PubMed ID: 23235319
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.
Ko AH; Quivey JM; Venook AP; Bergsland EK; Dito E; Schillinger B; Tempero MA
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):809-16. PubMed ID: 17363191
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas.
Senderowicz AM; Johnson JR; Sridhara R; Zimmerman P; Justice R; Pazdur R
Oncology (Williston Park); 2007 Dec; 21(14):1696-706; discussion 1706-9, 1712, 1715. PubMed ID: 18247017
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
Ko AH; Venook AP; Bergsland EK; Kelley RK; Korn WM; Dito E; Schillinger B; Scott J; Hwang J; Tempero MA
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1051-7. PubMed ID: 20130876
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis.
Yang ZY; Yuan JQ; Di MY; Zheng DY; Chen JZ; Ding H; Wu XY; Huang YF; Mao C; Tang JL
PLoS One; 2013; 8(3):e57528. PubMed ID: 23472089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
